LinkDoc’s US Listing In Jeopardy Following China's New Data Security Requirements
Executive Summary
The US listing of Chinese artificial intelligence, medical records and patient management system company Linkdoc could be derailed, after China issued new data review requirements tightening the oversight of overseas listings of domestic companies.
You may also be interested in...
Medtechs Must Gear Up For New China Data Protection Rules
China ambitiously wants to champion domestic medtech manufacturers in the global market. It also needs to ensure foreign manufacturers do not sustainably dominate its home market – while also benefiting from their technical expertise, for the time being at least. Against that backdrop, new Chinese data laws are being eyed by global medtechs with a certain trepidation.
China’s Threat To Global Medtech Markets Is Rising
China’s economic might and industrial drive are being felt increasingly in medtech, and the just-released 14th five-year plan will give Chinese manufacturers more support for expansion, both at home and in overseas markets. Should EU and US industries be worried?
Massive Selloff Hits US, HK-Listed China Health Cos, Clouds Sunny Prospects
Both Nasdaq- and Hong Kong-listed shares in Chinese health-related companies have been free falling with heavy volumes, after foreign investors spooked by China's general crackdown on the tech sector rushed to exit. The two-day sell-off shows high uncertainty and investors' anxiety over the regulatory overreach but underlying fundamentals still seem strong.